Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286804 · ClinicalTrials.gov registry record · NA
Ultherapy for the Treatment of Spider Veins on the Legs
A NA study of Telangiectasia and Spider Veins, sponsored by Ulthera.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02286804 is a NA study of Telangiectasia and Spider Veins that has completed, run by Ulthera. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02286804, a NA study of Telangiectasia and Spider Veins, has completed, sponsored by Ulthera.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 30 enrolled subjects will be treated. Enrolled subjects will receive Ultherapy® treatments along each length of the spider vein. Follow-up visits will occur at 30 and 60 days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.
Conditions Studied
Interventions
- DEVICE Ultherapy
Study Locations (1)
Arizona
- Ulthera, Inc. - Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02286804
The ClinicalTrials.gov registry entry for NCT02286804 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ulthera, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Telangiectasia appearing as the primary indexed condition, and to 1 intervention - of which Ultherapy is the first listed.
NCT02286804 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02286804 about?
NCT02286804 is a clinical study titled "Ultherapy for the Treatment of Spider Veins on the Legs". Up to 30 enrolled subjects will be treated. Enrolled subjects will receive Ultherapy® treatments along each length of the spider vein. Follow-up visits will occur at 30 and 60 days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.
What is the current status of trial NCT02286804?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2014-10. Estimated completion is 2015-05.
What conditions does trial NCT02286804 study?
This clinical trial studies the following conditions: Telangiectasia, Spider Veins.
What interventions are being tested in trial NCT02286804?
The interventions under investigation include: Ultherapy (DEVICE).
Who is sponsoring clinical trial NCT02286804?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02286804 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.